When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AEZS - Aeterna Zentaris to launch second pivotal study for its lead asset next year
Aeterna Zentaris Inc.
Aeterna Zentaris (AEZS-1.8%) said it is preparing for Phase 3 (AEZS-130-P02) safety, efficacy study for its lead product macimorelin, and expects to commence the study in Q1 of 2021. The company is currently developing the product for the diagnosis of child-onset growth hormone deficiency (CGHD), in collaboration with Novo Nordisk.
More news on: Aeterna Zentaris Inc., Healthcare stocks news,